Pozen, Inc. (
Q3 2010 Earnings Call
October 28, 2010 11:00 am ET
Stephanie Bonestell - IR
John Plachetka - Chairman, President and CEO
Liz Cermak - EVP and COO
Bill Hodges - SVP Finance & Administration and CFO
Jonathan Aschoff - Brean Murray
Michael Tong - Wells Fargo
Ian Anderson - Cowen & Company
Eun Yang - Jefferies & Company
Jason Napodano - Zacks Investment Research
Greetings and welcome to the POZEN Incorporated Third Quarter 2010 Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions). As a reminder this conference is being recorded.
It is now my pleasure to introduce your host, Stephanie Bonestell, Investor Relations. Thank you Ms. Bonestell. You may begin.
Thank you, Rob and good morning. On behalf of POZEN, I would like to welcome everyone to today's third quarter conference call. By now, you should have received a copy of the company's press release. If you do not have it, you can access it on the homepage of our website at www.pozen.com where you can also access the replay of this conference call.
Before we begin, I need to remind you that various remarks that we may make about future expectations, plans and prospects for the company, constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.
Such statements include, any observations that we may make about the expected timing and amounts of royalty payments from GlaxoSmithKline and AstraZeneca and other revenue expected from our collaboration partners. The prospects for approval or timing of approval of any of our drug candidates or the way in which the FDA may consider our new drug applications or particular trial results, future trial plans and the likelihood of results of any of any future trials, and our potential commercialization plans for our product candidates.